Zota Health Care Shares Rated New 'Buy' At Nirmal Bang - Check Target Price, Potential Upside And More

ADVERTISEMENTZota Health Care Shares Rated New 'Buy' At Nirmal Bang — Check Target Price, Potential Upside And MoreNirmal Bang initiates coverage on Zota Health with a 'Buy' rating citing strong growth trajectory. Nirmal Bang Institutional Research12 Dec 2025, 10:45 AM IST i12 Dec 2025, 10:45 AM IST12 Dec 2025, 10:45 AM ISTSaveDavaindia contributes ~64% of Zota’s FY25 revenue and remains the company’s most important long-term growth driver.(Photo: Zota website) Industry tailwinds—such as rising chronic disease burden, affordability pressures, and government push for generics—reinforce Zota’s positioning as a structural winner in India’s evolving pharmaceutical retail landscape. To continue reading this storyYou must be an existing Premium UserAlready a Premium User? Sign InWatch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit.